Loading...
Market
What will be Biogen's revenue for Q4 2024?
3
Resolution / Starting Odds
Below $2.4 billion • 25%
$2.4 billion to $2.5 billion • 25%
$2.5 billion to $2.6 billion • 25%
Above $2.6 billion • 25%
Biogen's Q4 2024 earnings report
Story
Biogen Raises Guidance as Leqembi Sales Boost Q3 Earnings, Stock Rises
Oct 31, 2024, 10:38 AM
Biogen Inc. reported stronger-than-expected third-quarter earnings for 2024 and raised its full-year earnings guidance, as cost-cutting measures helped offset declining sales of its multiple sclerosis medications. The company increased its full-year non-GAAP diluted EPS guidance to between $16.10 and $16.60, up from the previous range of $15.75 to $16.25. Biogen's revenue for the quarter was $2.5 billion, with GAAP diluted EPS of $2.66 and non-GAAP diluted EPS of $4.08, surpassing analysts' estimates. Sales of its Alzheimer's drug Leqembi contributed to the positive results, generating global in-market sales of $67 million, including $39 million in the United States. The company's stock rose after the announcement, reflecting investor optimism in Biogen's performance and outlook.
View original story
Similar markets
Below $8 billion • 25%
$8 billion to $10 billion • 25%
$10 billion to $12 billion • 25%
Above $12 billion • 25%
Above $100 million • 25%
Between $50 million and $100 million • 25%
Between $10 million and $50 million • 25%
Below $10 million • 25%
More than 20% increase • 25%
10%-20% increase • 25%
0%-10% increase • 25%
Decrease • 25%
Below $5 billion • 25%
$5 - $5.49 billion • 25%
$5.5 - $5.99 billion • 25%
$6 billion or above • 25%
Below $9 billion • 25%
$9 billion to $9.5 billion • 25%
$9.51 billion to $10 billion • 25%
Above $10 billion • 25%
Above $50 billion • 33%
$40 billion to $50 billion • 33%
Below $40 billion • 34%
Below $27.1 billion • 25%
$27.1 billion to $27.3 billion • 25%
$27.31 billion to $27.5 billion • 25%
Above $27.5 billion • 25%
Less than $300M • 33%
$300M - $500M • 33%
More than $500M • 33%
Below $21 billion • 25%
$21 billion to $22 billion • 25%
$22 billion to $23 billion • 25%
Above $23 billion • 25%
Higher than competitors • 25%
On par with competitors • 25%
Lower than competitors • 25%
Significantly lower than competitors • 25%
Less than $10 billion • 25%
$10 billion to $12 billion • 25%
$12 billion to $14 billion • 25%
More than $14 billion • 25%
